CropLogic moves a step closer to monetising hemp crop
Shares in AgTech group CropLogic Ltd (ASX:CLI) opened higher on Tuesday morning after management confirmed that the group had met another milestone in completing planting at its Hemp Trial Farm in Central Oregon.
This season, CropLogic’s wholly owned subsidiary LogicalCropping will crop 500 acres of CBD producing hemp at its Hemp Trial Farm in Central Oregon.
The completion of planning represents another box ticked by management, reinforcing its track record in terms of delivering on expectations.
Next steps include the installation and utilisation of CropLogic’s suite of agtech products such as CropLogic realTime and CropLogic Aerial Imagery, as well as implementation of a fertigation strategy.
Commenting on the critical nature of this development, CropLogic chief executive James Cooper-Jones said, "The first 3 days and then the first 3 weeks are critical times in any cropping operations as this is the time that determines whether plants will ‘take’.
‘’Considering this, it is also encouraging to see the first plantings are ‘taking’ well and showing good growth.”
More milestones on the horizon
The company could well receive further share price support over the coming months as news regarding growth and flowering emerges in August/September, followed by compliance testing and harvesting in September/October.
At the start of May FinFeed highlighted CropLogic’s impressive earnings outlook with this year’s crop expected to generate underlying earnings of approximately $40 million based on a healthy yield and mid-range costs of production and sales estimates.
Since then CropLogic’s shares have doubled, and no doubt as the company draws closer to realising its anticipated earnings its share price will respond accordingly.
Given the company’s market capitalisation of $22 million implies a substantial discount to other profitable agricultural producers, a rerating could be significant.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.